Emory University: Leukemia trials

The registry lists 16 Leukemia studies with Emory University as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 6Phase 2 5No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• AflacLL1901 (CHOA-AML)TerminatedNCT04326439Phase 2Results posted
• Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsTerminatedNCT02877082Phase 2Results posted
• Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid LeukemiaTerminatedNCT02730195Phase 2Results posted
• Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid LeukemiaTerminatedNCT02709083Phase 2Results posted
• Rituximab for Patients With Relapsed Acute Lymphoblastic LeukemiaTerminatedNCT01230788Not applicableResults posted
• Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic TransplantationCompletedNCT00548847Phase 2Results posted
• Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/LymphomaCompletedNCT03328104Phase 1
• Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid LeukemiaWithdrawnNCT02680951Phase 1
• Improving Patient Education for Lymphoma and Leukemia InpatientsCompletedNCT02642510Not applicable
• Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT02614508Phase 1
• Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a DatabaseTerminatedNCT02309333
• Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic TransplantationNo longer availableNCT02258490
• AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute LeukemiaTerminatedNCT01655875Phase 1
• A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)TerminatedNCT01005979Phase 1
• Intraosseous Infusion of Unrelated Cord Blood GraftsTerminatedNCT00967525Not applicable
• Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT00957320Phase 1